VERU INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VERU INC. on September 22, 2025, regarding the termination of a material definitive agreement. The filing details a settlement reached with Onconetix, Inc. (formerly Blue Water Vaccines Inc.) to resolve outstanding obligations under promissory notes stemming from an asset purchase agreement dated April 19, 2023.
Key Financial Metrics and Transaction Details
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, or margins. The report focuses exclusively on the resolution of a specific debt obligation.
- Total Amount Payable: $8,826,155.41 (aggregate principal and interest due under the Promissory Notes as of September 22, 2025).
- Cash Settlement Received: $6,326,155.41.
- Equity Settlement Received: 3,125 shares of Onconetix Series D Convertible Preferred Stock (stated value $1,000 per share).
- Warrants Received: 846,975 warrants to purchase Onconetix common stock.
- Debt Reduction: Full discharge of the $5,000,000 April 2024 Promissory Note and the $5,000,000 September 2024 Promissory Note.
Material Changes and Settlement Terms
On September 22, 2025, VERU and Onconetix entered into a Settlement Agreement and Release. This agreement terminated the Amended Forbearance Agreement and the underlying Promissory Notes. The settlement was executed on September 24, 2025, upon payment of the settlement amounts. The transaction resulted in a reduction of the receivable balance by approximately $2.5 million, with the difference satisfied through the issuance of equity and warrants rather than cash.
Outlook, Risks, and Management Commentary
Management notes that while the debt obligation has been discharged, there is no assurance regarding the timing or ability to realize cash proceeds from the Series D Preferred Stock or the Warrants. The Preferred Stock is convertible into common stock at the Company's option, and the Borrower retains redemption rights under certain circumstances. The value of the non-cash settlement components remains contingent on the future performance and liquidity of Onconetix.
Key Facts for Investor Verification
- Verify the fair market value of the 3,125 Series D Preferred Stock shares and 846,975 warrants received to assess the true economic recovery rate of the $8.8 million receivable.
- Review the terms of the Series D Preferred Stock conversion and redemption rights to understand potential dilution or liquidity constraints.
- Confirm the financial stability of Onconetix, Inc., as the realization of value from the equity and warrant components depends on the Borrower's future viability.
- Check for any subsequent filings regarding the exercise of warrants or conversion of preferred stock.